Wedbush Has Positive Forecast for Prime Medicine Q2 Earnings

Prime Medicine, Inc. (NYSE:PRME) – Analysts at Wedbush upped their Q2 2025 earnings per share (EPS) estimates for shares of Prime Medicine in a research note issued on Wednesday, July 16th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.40) per share for the quarter, up from their prior forecast of ($0.41). Wedbush has a “Outperform” rating and a $8.00 price objective on the stock. The consensus estimate for Prime Medicine’s current full-year earnings is ($1.68) per share. Wedbush also issued estimates for Prime Medicine’s Q3 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.39) EPS, FY2026 earnings at ($0.92) EPS, FY2027 earnings at ($0.81) EPS and FY2028 earnings at ($0.84) EPS.

Several other analysts also recently weighed in on PRME. JMP Securities reduced their target price on Prime Medicine from $10.00 to $6.00 and set a “market outperform” rating for the company in a report on Tuesday, May 20th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Prime Medicine in a research note on Tuesday, May 20th. HC Wainwright lowered Prime Medicine from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 20th. Citigroup reaffirmed a “neutral” rating and issued a $1.50 target price (down from $10.00) on shares of Prime Medicine in a research report on Tuesday, May 27th. Finally, Chardan Capital lowered their price target on Prime Medicine from $16.00 to $12.00 and set a “buy” rating for the company in a report on Monday, May 19th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.25.

Prime Medicine Stock Performance

Prime Medicine stock opened at $4.13 on Friday. Prime Medicine has a fifty-two week low of $1.11 and a fifty-two week high of $6.40. The company has a market capitalization of $555.60 million, a P/E ratio of -2.01 and a beta of 2.33. The stock has a 50-day simple moving average of $2.18 and a 200-day simple moving average of $2.22.

Insider Transactions at Prime Medicine

In other Prime Medicine news, major shareholder David R. Liu bought 21,000 shares of the business’s stock in a transaction on Monday, June 23rd. The shares were purchased at an average price of $2.16 per share, with a total value of $45,360.00. Following the completion of the acquisition, the insider directly owned 20,219,945 shares of the company’s stock, valued at approximately $43,675,081.20. The trade was a 0.10% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders have bought a total of 63,000 shares of company stock valued at $110,250 over the last quarter. Company insiders own 22.93% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. ProShare Advisors LLC grew its position in Prime Medicine by 24.6% during the 4th quarter. ProShare Advisors LLC now owns 22,186 shares of the company’s stock worth $65,000 after purchasing an additional 4,375 shares in the last quarter. Rhumbline Advisers grew its position in Prime Medicine by 13.8% during the 1st quarter. Rhumbline Advisers now owns 81,900 shares of the company’s stock worth $163,000 after purchasing an additional 9,944 shares in the last quarter. American Century Companies Inc. purchased a new position in Prime Medicine during the 4th quarter worth approximately $33,000. Virtus ETF Advisers LLC grew its position in Prime Medicine by 102.4% during the 4th quarter. Virtus ETF Advisers LLC now owns 23,618 shares of the company’s stock worth $69,000 after purchasing an additional 11,948 shares in the last quarter. Finally, Barclays PLC grew its position in Prime Medicine by 15.3% during the 4th quarter. Barclays PLC now owns 97,621 shares of the company’s stock worth $285,000 after purchasing an additional 12,924 shares in the last quarter. Institutional investors and hedge funds own 70.37% of the company’s stock.

About Prime Medicine

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.